Olmesartan/Amlodipine/Hct Eg (Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate)

Olmesartan medoxil is an angiotensin II receptor blocker that selectively inhibits the AT‑1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone secretion. This results in relaxed blood vessels and reduced fluid retention, contributing to lower systemic blood pressure.

The dosage is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall treatment plan. Physicians determine the appropriate strength and frequency according to clinical guidelines and patient response.

The combination is contraindicated in pregnancy because angiotensin‑II receptor blockers can cause fetal toxicity. Breastfeeding is not recommended unless the benefit outweighs potential risk, and the prescriber should evaluate safety for the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with single‑agent therapy, the Olmesartan/Amlodipine/Hct Eg combo offers three mechanisms—ARB, calcium‑channel blockade, and thiazide diuresis—in one tablet, which can improve adherence and provide more consistent blood‑pressure control than adding separate pills. It is often considered when monotherapy does not achieve target pressures.

Store the tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the prescribing clinician’s instructions regarding timing and any dose adjustments.

Serious adverse events can include severe hypotension, hyperkalaemia, acute kidney injury, angio‑edema and significant electrolyte disturbances. Prompt medical attention is required if symptoms such as fainting, swelling of the face or throat, or marked changes in urine output occur.

Patients with known hypersensitivity to any component of the combination, those with severe renal impairment, hyperkalaemia, or who are pregnant should avoid this product. Clinicians should also exercise caution in elderly patients and those with hepatic disease.